|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
SG194176A1
(en)
*
|
2011-05-27 |
2013-12-30 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
EP2914628A1
(en)
|
2012-11-01 |
2015-09-09 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
TW201425336A
(zh)
*
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
ES2667420T3
(es)
|
2013-02-05 |
2018-05-10 |
Engmab Sàrl |
Anticuerpos biespecíficos contra cd3epsilon y bcma
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
CN110845618A
(zh)
*
|
2013-02-26 |
2020-02-28 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
US20160015749A1
(en)
*
|
2013-03-05 |
2016-01-21 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
PL2968555T3
(pl)
|
2013-03-13 |
2020-11-16 |
Sanofi |
Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
|
|
AR095374A1
(es)
*
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
KR20230004939A
(ko)
|
2014-02-07 |
2023-01-06 |
맥마스터 유니버시티 |
3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
|
|
EP3126826B1
(en)
|
2014-04-04 |
2020-12-16 |
Mayo Foundation for Medical Education and Research |
Isotyping immunoglobulins using accurate molecular mass
|
|
KR102526945B1
(ko)
|
2014-04-30 |
2023-04-27 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Ｃｄ269에 대한 인간화 항체
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3023437A1
(en)
*
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
CA2969877A1
(en)
|
2014-12-05 |
2016-06-09 |
Memorial Sloan-Kettering Cancer Center |
Antibodies targeting b-cell maturation antigen and methods of use
|
|
EP4310097A3
(en)
|
2014-12-05 |
2024-04-03 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
PL3988117T3
(pl)
|
2015-04-13 |
2025-03-10 |
Pfizer Inc. |
Przeciwciała terapeutyczne i ich zastosowania
|
|
JP6921001B2
(ja)
|
2015-04-13 |
2021-08-18 |
ファイザー・インク |
Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
|
|
PL3294319T3
(pl)
*
|
2015-05-13 |
2024-10-07 |
Ablynx Nv |
Polipeptydy rekrutujące komórki t na podstawie reaktywności cd3
|
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
WO2016196612A1
(en)
*
|
2015-06-01 |
2016-12-08 |
The Rockefeller University |
Anti-tumor agents and methods of use
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EP3670535A1
(en)
*
|
2015-08-03 |
2020-06-24 |
EngMab Sàrl |
Monoclonal antibodies against bcma
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
TWI811023B
(zh)
*
|
2015-08-17 |
2023-08-01 |
美商健生生物科技公司 |
抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
|
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究（慕尼黑）公司 |
包含雙特異性抗體建構物之醫藥組合物
|
|
IL313507A
(en)
*
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
TN2018000266A1
(en)
|
2016-02-03 |
2020-01-16 |
Amgen Res Munich Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs.
|
|
US20190194338A1
(en)
|
2016-02-17 |
2019-06-27 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
PT3461261T
(pt)
|
2016-05-20 |
2025-07-31 |
Harpoon Therapeutics Inc |
Proteínas de ligação ao cd3 de fragmento variável de cadeia única
|
|
CA3024723A1
(en)
|
2016-05-20 |
2017-11-23 |
Robert B. Dubridge |
Single domain serum albumin binding protein
|
|
WO2017223111A1
(en)
*
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
HRP20240767T1
(hr)
*
|
2016-09-14 |
2024-09-13 |
Teneoone, Inc. |
Cd3 vezujuća antitijela
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
CA3043515A1
(en)
|
2016-11-16 |
2018-05-24 |
Ablynx Nv |
T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
|
|
EP3544997A4
(en)
|
2016-11-23 |
2020-07-01 |
Harpoon Therapeutics, Inc. |
PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
|
|
KR20190087539A
(ko)
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
Psma 표적화 삼중특이성 단백질 및 사용 방법
|
|
BR112019012354A2
(pt)
*
|
2016-12-21 |
2019-11-26 |
Teneobio, Inc. |
anticorpos apenas de cadeia pesada anti-bcma
|
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
CN110461335A
(zh)
|
2017-02-17 |
2019-11-15 |
弗雷德哈钦森癌症研究中心 |
用于治疗bcma相关癌症和自身免疫性失调的联合疗法
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
BR112019023855B1
(pt)
|
2017-05-12 |
2021-11-30 |
Harpoon Therapeutics, Inc |
Proteínas de ligação à mesotelina
|
|
CN115028727A
(zh)
|
2017-05-12 |
2022-09-09 |
哈普恩治疗公司 |
靶向msln的三特异性蛋白质及使用方法
|
|
CA3063598A1
(en)
|
2017-06-14 |
2018-12-20 |
Dana-Farber Cancer Institute, Inc. |
B-cell maturation antigen (bcma)-directed nanoparticles
|
|
CN110891971B
(zh)
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
MX2019015563A
(es)
|
2017-06-20 |
2020-07-28 |
Teneoone Inc |
Anticuerpos anti-bcma unicamente de cadena pesada.
|
|
WO2019000223A1
(en)
*
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
IL297824A
(en)
*
|
2017-09-15 |
2023-01-01 |
Amgen Inc |
Process for lyophilized pharmaceutical formulation of a therapeutic protein
|
|
JP2020535181A
(ja)
*
|
2017-09-29 |
2020-12-03 |
ヤンセン バイオテツク，インコーポレーテツド |
低用量抗体組成物を安定化する新規製剤
|
|
JP7227630B2
(ja)
|
2017-10-12 |
2023-02-22 |
マックマスター ユニバーシティー |
Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
|
|
IL315737A
(en)
*
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
JP7084990B2
(ja)
|
2017-10-13 |
2022-06-15 |
ハープーン セラピューティクス，インク． |
三重特異性タンパク質と使用方法
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
KR102845789B1
(ko)
|
2017-11-01 |
2025-08-14 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
|
|
KR20200074997A
(ko)
*
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
|
US12193994B2
(en)
|
2017-11-06 |
2025-01-14 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
SG11202004512XA
(en)
|
2017-11-15 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
CA3083949A1
(en)
|
2017-11-30 |
2020-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
CA3086665A1
(en)
|
2017-12-22 |
2019-06-27 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd22
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3759146A1
(en)
|
2018-03-02 |
2021-01-06 |
CDR-Life AG |
Trispecific antigen binding proteins
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
CA3100157A1
(en)
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
CN119529091A
(zh)
*
|
2018-06-19 |
2025-02-28 |
南京传奇生物科技有限公司 |
工程化的细胞及其用途
|
|
WO2020004934A1
(ko)
|
2018-06-26 |
2020-01-02 |
에이비엘바이오 주식회사 |
항-bcma 항체 및 그 용도
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
EA202190315A1
(ru)
|
2018-07-19 |
2021-04-16 |
Ридженерон Фармасьютикалз, Инк. |
Химерные антигенные рецепторы со специфичностью к bcma и их применение
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844267B1
(en)
|
2018-08-31 |
2025-06-25 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
BR112021008486A2
(pt)
*
|
2018-11-01 |
2021-10-26 |
Shandong New Time Pharmaceutical Co., Ltd |
Anticorpo biespecífico e seu uso
|
|
MX2021005024A
(es)
|
2018-11-01 |
2021-07-21 |
Juno Therapeutics Inc |
Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
AU2020252556B2
(en)
|
2019-04-05 |
2026-02-05 |
Teneobio, Inc. |
Heavy chain antibodies binding to PSMA
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
TWI905099B
(zh)
|
2019-05-21 |
2025-11-21 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
DK3819007T3
(da)
*
|
2019-11-11 |
2024-09-30 |
Amgen Res Munich Gmbh |
Doseringsplan for anti-bcma-midler
|
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
|
KR20220146530A
(ko)
|
2020-02-27 |
2022-11-01 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포의 제조 방법
|
|
MX2022013453A
(es)
|
2020-04-29 |
2022-11-16 |
Teneobio Inc |
Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
|
|
CA3182697A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
US20210363252A1
(en)
|
2020-05-19 |
2021-11-25 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
IL299027A
(en)
*
|
2020-06-30 |
2023-02-01 |
Teneobio Inc |
Multispecific antibodies that bind BCMA
|
|
EP4202047A4
(en)
*
|
2020-08-20 |
2024-09-18 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
UNIQUE VARIABLE STRUCTURAL DOMAIN FOR BCMA BINDING AND ANTIGEN BINDING MOLECULE
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
WO2022126416A1
(zh)
*
|
2020-12-16 |
2022-06-23 |
武汉友芝友生物制药股份有限公司 |
抗bcma抗体及其制备方法和应用
|
|
SI4284512T1
(sl)
|
2021-01-28 |
2025-06-30 |
Regeneron Pharmaceuticals, Inc. |
Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
|
|
EP4304728A4
(en)
*
|
2021-03-09 |
2025-08-20 |
Harpoon Therapeutics Inc |
COMBINATION THERAPY WITH IMMUNE CELL CONTACT PROTEINS AND IMMUNOMODULATORS
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
JP2024513559A
(ja)
*
|
2021-04-09 |
2024-03-26 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規なＤＡＲＰｉｎベースのＣＤ７０エンゲージャー
|
|
AU2022267891A1
(en)
|
2021-04-27 |
2023-11-09 |
Novartis Ag |
Viral vector production system
|
|
KR20240037892A
(ko)
|
2021-06-01 |
2024-03-22 |
트리움비라 이뮤놀로직스 유에스에이, 인크. |
클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
|
|
CN119569887A
(zh)
*
|
2021-06-24 |
2025-03-07 |
益科思特(北京)医药科技发展有限公司 |
结合bcma和cd3的双特异性抗体及其制备方法与应用
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
WO2023021477A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor–expressing cells
|
|
KR20240099376A
(ko)
|
2021-11-03 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
|
|
US20230357446A1
(en)
|
2022-04-11 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
IL322545A
(en)
|
2023-02-17 |
2025-10-01 |
Regeneron Pharma |
Induced NK cells responding to bispecific CD3/TAA antibodies
|
|
WO2024206329A1
(en)
*
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|